Lifeline Scientific, Inc Posting of Annual Report & Notice of AGM (0619Z)
May 24 2016 - 2:00AM
UK Regulatory
TIDMLSIC
RNS Number : 0619Z
Lifeline Scientific, Inc
24 May 2016
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Posting of Annual Report & Notice of AGM
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, confirms that the Annual Report and Accounts for the year
ended 31 December 2015 ('2015 Annual Report and Accounts'), the
Notice of Annual General Meeting ('AGM') and a Form of Proxy were
posted to shareholders on 20 May 2016.
The AGM is to be held at 8.30am US CDT on 23 June 2016 at the
Westin Hotel, 400 Park Boulevard, Itasca, IL 60143, USA.
A copy of the 2015 Annual Report and Accounts is available on
the Company's website: www.lifeline-scientific.com
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Tom Salvesen (Corporate
Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Lianne Cawthorne Mob: +44 (0)7584 391 303
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of donor kidneys. Employed by surgeons in
over 206 leading transplant programmes in 29 countries, LifePorts
have successfully preserved more than 70,000 kidneys indicated for
clinical transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and international
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specialising in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXSDAELKEFF
(END) Dow Jones Newswires
May 24, 2016 02:00 ET (06:00 GMT)
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
From Aug 2023 to Aug 2024